Özdemir Sonay İncesoy, Akcan Gülben, Tufan Ahmet Çevik, Erdem Arzu Yazal, Çakmakcı Selma, Özyörük Derya, Sarı Neriman, Tufan Naciye Lale Şatıroğlu, İlhan İnci Ergürhan
Division of Pediatric Oncology, Department of Pediatrics, Faculty of Medicine, Ankara University, Ankara, Turkey.
Department of Histology and Embryology, Faculty of Medicine, KTO Karatay University, Konya, Turkey.
Eur J Pediatr. 2025 Jan 6;184(1):116. doi: 10.1007/s00431-024-05949-x.
Osteosarcoma (OS) bone tumor of childhood although the etiology of OS has not been fully elucidated, there is evidence linking it with factors related to pubertal development. In recent years, plasma CNP concentration and height velocity in children and CNP have been implicated as an emerging new growth marker during childhood. We aimed to determine the serum NT-proCNP levels of patients with pediatric osteosarcoma and its relation with clinical-laboratory growth parameters and look for any correlation of serum NT-proCNP levels with different prognostic factors in childhood osteosarcoma. This study enrolled 15 newly diagnosed OS patients and 31 healthy controls. All subjects were physically examined. Plasma NT-proCNP concentration was measured by enzyme-linked immunosorbent assay. Our results demonstrated that serum NT-proCNP concentration was significantly different between OS patients and control groups. At diagnosis, the OS patient's mean blood NT-proCNP concentration was 49.7 ± 3.3 pmol/l, which was substantially lower than the control group's concentration of 61.4 ± 3.10 pmol/l (p < 0.005). No significant correlation was found between serum NT-proCNP concentration and growth parameters.
In conclusion, we found that the serum NT-proCNP concentration was significantly different between OS patients and control groups. It is predicted that our results will contribute to osteosarcoma biology.
• Osteosarcoma (OS) is the most common malignant bone tumor of childhood, affecting rapidly growing bones with factors associated with rapid bone growth, although its etiology is not fully understood. • The current literature suggests that the main role of the CNP/NPR-B signaling pathway is associated with endochondral bone development and related growth in long bones.
• We demonstrated that serum NT-proCNP concentration was significantly different between OS patients and control groups and could be used as a potential biomarker. • To our knowledge, this is the first clinical study evaluating the relation of serum serum NT-proCNP levels with anthropometric parameters in osteosarcoma patient with a particular interest to identify the possible role of CNP in pediatric osteosarcoma and its relationship with prognostic factors.
骨肉瘤(OS)是儿童期的骨肿瘤,尽管骨肉瘤的病因尚未完全阐明,但有证据表明其与青春期发育相关因素有关。近年来,儿童血浆CNP浓度和身高增长速度以及CNP被认为是儿童期一种新出现的生长标志物。我们旨在测定小儿骨肉瘤患者的血清NT-proCNP水平及其与临床实验室生长参数的关系,并寻找血清NT-proCNP水平与儿童骨肉瘤不同预后因素之间的任何相关性。本研究纳入了15例新诊断的骨肉瘤患者和31名健康对照。对所有受试者进行了体格检查。采用酶联免疫吸附测定法测量血浆NT-proCNP浓度。我们的结果表明,骨肉瘤患者和对照组之间血清NT-proCNP浓度存在显著差异。在诊断时,骨肉瘤患者的平均血液NT-proCNP浓度为49.7±3.3 pmol/l,显著低于对照组的浓度61.4±3.10 pmol/l(p<0.005)。血清NT-proCNP浓度与生长参数之间未发现显著相关性。
总之,我们发现骨肉瘤患者和对照组之间血清NT-proCNP浓度存在显著差异。预计我们的结果将有助于骨肉瘤生物学研究。
•骨肉瘤(OS)是儿童期最常见的恶性骨肿瘤,影响快速生长的骨骼,其病因虽未完全明确,但与快速骨生长相关因素有关。•当前文献表明,CNP/NPR-B信号通路的主要作用与软骨内骨发育及长骨相关生长有关。
•我们证明骨肉瘤患者和对照组之间血清NT-proCNP浓度存在显著差异,可作为一种潜在的生物标志物。•据我们所知,这是第一项评估骨肉瘤患者血清NT-proCNP水平与人体测量参数关系的临床研究,特别关注确定CNP在小儿骨肉瘤中的可能作用及其与预后因素的关系。